Dear Colleagues and Friends,

We are delighted to invite you to the Clinical Working Party of the European Society of Immunodeficiencies, which will be held online from 27-29 September 2021.

Modern treatment of inflammatory disease or malignancy increasingly targets specific elements of the immune system through cellular therapies (eg CAR-T cells), targeted monoclonal antibodies directed against specific cytokines or receptors (eg anakinra) or cells (eg alemtuzumab) or small molecules targeting signaling pathways (eg  JAK inhibitors). Whilst effective at treating the disease, the unintended effect of these therapies may lead to phenocopies of primary immunodeficiencies, which may not be noticed, resulting in secondary immunodeficiencies.

There are currently no internationally agreed guidelines for the management of secondary immunodeficiencies resulting from use of these therapies.

This meeting will bring together specialists from a range of disciplines which use these immune modulating therapies, to discuss their mechanisms of action and side effects as well as the diagnosis and practical management of secondary immunodeficiencies

We look forward to meeting you soon online.

With very best wishes,